TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 38879802
Drug: Linvoseltamab 50
Normalized name: Linvoseltamab
DrugBank: Linvoseltamab (DB17447)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Linvoseltamab 50 mg
Study: 38879879
Drug: SPS tablets
Normalized name: SPS
Approvals — FDA: no, EMA: no, PMDA: no
Description: SPS tablets (n = 60; three tablets per dose, twice daily) for 24 weeks
Study: 38880111
Drug: RH5.1/Matrix-M vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: RH5.1/Matrix-M vaccine candidate (10 μg RH5.1 at 0, 1, and 2 months for Adults 10M; 50 μg RH5.1 at 0 and 1 month and 10 μg RH5.1 at 6 months for Adults DFx; 10 μg RH5.1 at 0, 1, and 2 months for Children 10M; 10 μg RH5.1 at 0, 1, and 6 months for Children 10D; Children DFx and High Children DFx with dose-escalation regimen)
Study: 38880111
Drug: Delayed third
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed third dose regimen (Children 10D)
Study: 38880111
Drug: RH5.1/Matrix-M vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: RH5.1/Matrix-M vaccine candidate
Study: 38880198
Drug: High-dose (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose (200 ppm for 30 min) + continuous low-dose (20 ppm) iNO
Study: 38880198
Drug: Intermittent high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent high-dose iNO
Study: 38880251
Drug: dupilumab 300
Normalized name: dupilumab 300 MG in 2 ML Auto-Injector
Approvals — FDA: no, EMA: no, PMDA: no
Description: dupilumab 300 mg every 2 weeks
Study: 38880785
Drug: Ad26.RSV.preF/RSV preF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ad26.RSV.preF/RSV preF protein vaccine (1 × 10 dose)
Study: 38880785
Drug: Ad26.RSV.preF/RSV preF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ad26.RSV.preF/RSV preF protein vaccine
Study: 38880932
Drug: BI 474121
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 474121 (3.0 mg/kg)
Study: 38880956
Drug: Tofacitinib (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tofacitinib (5 or 10 mg twice daily)
Study: 38881506
Drug: Heplisav-B (HepB-CpG)
Normalized name: HepB-CpG
DrugBank: Hepatitis B Vaccine (Recombinant) (DB11627)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heplisav-B (HepB-CpG) 2-dose series
Study: 38881506
Drug: Heplisav-B (HepB-CpG)
Normalized name: HepB-CpG
DrugBank: Hepatitis B Vaccine (Recombinant) (DB11627)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heplisav-B (HepB-CpG) 1-dose
Study: 38881599
Drug: EYP-1901 (440
Approvals — FDA: no, EMA: no, PMDA: no
Description: EYP-1901 (440 μg, 1030 μg, 2060 μg, 3090 μg)
Study: 38881900
Drug: Monoclonal anti-idiotypic
Normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Monoclonal anti-idiotypic (anti-ID) antibody positive controls
Study: 38883740
Drug: Ribociclib (CDK4/6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ribociclib (CDK4/6 inhibitor) and Everolimus (mTOR inhibitor)
Study: 38883743
Drug: Self-administered intravaginal
Normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Self-administered intravaginal 5% fluorouracil (5FU) cream, 2g every other week for eight applications.
Study: 38883743
Drug: Self-administered intravaginal
Normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Self-administered intravaginal 5% fluorouracil (5FU) cream
Study: 38883779
Drug: Intratumoral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intratumoral administration of anti-CD40 agonistic antibody (2141-V11)
Study: 38884332
Drug: Reteplase (18
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reteplase (18 mg bolus followed by another 18 mg bolus 30 minutes later)
Study: 38884987
Drug: Nicotine-containing electronic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine-containing electronic cigarettes (ECs) 18 mg/mL with placebo tablets
Study: 38884987
Drug: Varenicline with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Varenicline with standard dosing and nicotine-free ECs
Study: 38884987
Drug: Placebo tablets
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets with nicotine-free ECs
Study: 38885234
Drug: Glenzocimab (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glenzocimab (1000 mg/day for 3 days)
Study: 38885246
Drug: Rucaparib 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rucaparib 600 mg by mouth twice daily
Study: 38885481
Drug: BAFF-R CAR
Normalized name: pantolactone, (R)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: BAFF-R CAR T-cell therapy
Study: 38885482
Drug: SARS-CoV-2-specific CTLs
Normalized name: SARS-COV
Approvals — FDA: no, EMA: no, PMDA: no
Description: SARS-CoV-2-specific CTLs (1 of 4 escalating doses, containing 68.5% SARS-CoV-2-specific CD8+ CTLs/total cells)
Study: 38885672
Drug: Sovleplenib (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sovleplenib (300 mg once daily for 24 weeks)
Study: 38885985
Drug: Concurrent Substance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent Substance Use and Hazardous Drinking (SU and HD)
Study: 38885990
Drug: qER solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: qER solution with prioritised flag in the radiology information system (post-implementation phase)
Study: 38886159
Drug: Entinostat 5
Normalized name: entinostat
DrugBank: Entinostat (DB11841)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Entinostat 5 mg weekly
Study: 38886347
Drug: FS-1502 (anti-HER2
Approvals — FDA: no, EMA: no, PMDA: no
Description: FS-1502 (anti-HER2 ADC) at recommended phase 2 dose (RP2D) of 2.3 mg/kg once every 3 weeks.
Study: 38886347
Drug: FS-1502 (anti-HER2
Approvals — FDA: no, EMA: no, PMDA: no
Description: FS-1502 (anti-HER2 ADC) at doses of 3.0 and 3.5 mg/kg.
Study: 38886347
Drug: FS-1502 (anti-HER2
Approvals — FDA: no, EMA: no, PMDA: no
Description: FS-1502 (anti-HER2 ADC) at RP2D of 2.3 mg/kg.
Study: 38888616
Drug: zanubrutinib (160
Approvals — FDA: no, EMA: no, PMDA: no
Description: zanubrutinib (160 mg twice-daily)
Study: 38888616
Drug: ibrutinib (420
Approvals — FDA: no, EMA: no, PMDA: no
Description: ibrutinib (420 mg once-daily)
Study: 38888958
Drug: 8-week MBCT
Normalized name: lacosamide
DrugBank: Lacosamide (DB06218)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 8-week MBCT intervention plus treatment as usual (MBCT + TAU)
Study: 38889160
Drug: Outpatient treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Outpatient treatment for psychotic disorders
Study: 38889247
Drug: mRNA-1345 50-µg
Normalized name: mRNA-1345
DrugBank: mRNA-1345 (DB18739)
Approvals — FDA: no, EMA: no, PMDA: no
Description: mRNA-1345 50-µg vaccine
Study: 38889372
Drug: European Organisation
Approvals — FDA: no, EMA: no, PMDA: no
Description: European Organisation for Research and Treatment of Cancer QoL Core 30 questionnaire (QLQ-C30) summary score at diagnosis and 1 and 2 years postdiagnosis.
Study: 38889373
Drug: Amcenestrant 200
Normalized name: Amcenestrant
DrugBank: SAR-439459 (DB17864)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amcenestrant 200 mg once daily + palbociclib 125 mg once daily (21 days on/7 days off)
Study: 38889373
Drug: Letrozole 2.5
Normalized name: letrozole 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Letrozole 2.5 mg once daily + palbociclib 125 mg once daily (21 days on/7 days off)
Study: 38889431
Drug: Topical sildenafil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical sildenafil cream (3.6%)
Study: 38889737
Drug: Epcoritamab monotherapy
Normalized name: Epcoritamab
DrugBank: Epcoritamab (DB16672)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epcoritamab monotherapy
Study: 38890186
Drug: Low-level light/laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-level light/laser therapy (LLLT)
Study: 38890563
Drug: MaxiPost (0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: MaxiPost (0.05 mg/min)
Study: 38890641
Drug: eliapixant 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: eliapixant 25 mg BID
Study: 38890641
Drug: eliapixant 75
Approvals — FDA: no, EMA: no, PMDA: no
Description: eliapixant 75 mg BID
Study: 38890641
Drug: eliapixant 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: eliapixant 150 mg BID
Study: 38890641
Drug: elagolix 150
Normalized name: elagolix 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: elagolix 150 mg once daily
Study: 38890655
Drug: IV-DXN (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV-DXN (4 mg/ml DXN)
Study: 38890655
Drug: PN-DXN (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: PN-DXN (1 ml of 4 mg/ml DXN)
Study: 38890709
Drug: Online self-help
Normalized name: loratadine
DrugBank: Loratadine (DB00455)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Online self-help 14-day Acceptance and Commitment Therapy (ACT) training
Study: 38891799
Drug: Probiotic therapy
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic therapy for 12 weeks
Study: 38893184
Drug: Intraoperative radiotherapy
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraoperative radiotherapy (IORT) boost, single dose of 20 Gy, administered immediately after tumor resection.
Study: 38895199
Drug: Oral fluoropyrimidine
Normalized name: 5-Fluoropyrimidine-2,4-dione
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral fluoropyrimidine treatment
Study: 38896141
Drug: fSCIG 10%
Approvals — FDA: no, EMA: no, PMDA: no
Description: fSCIG 10% with conventional ramp-up at 1.0 g/kg/infusion
Study: 38896141
Drug: fSCIG 10%
Approvals — FDA: no, EMA: no, PMDA: no
Description: fSCIG 10% with no ramp-up at 1.0 g/kg/infusion
Study: 38896141
Drug: fSCIG 10%
Approvals — FDA: no, EMA: no, PMDA: no
Description: fSCIG 10% with accelerated ramp-up at 1.0 g/kg/infusion
Study: 38896141
Drug: fSCIG 10%
Approvals — FDA: no, EMA: no, PMDA: no
Description: fSCIG 10% with conventional ramp-up at 0.4 g/kg/infusion
Study: 38896199
Drug: Mirogabalin 15
Normalized name: mirogabalin
DrugBank: Mirogabalin (DB11825)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Mirogabalin 15 mg twice daily (after uptitration from 5 mg twice daily for the first week)
Study: 38896264
Drug: Alglucosidase alfa
Normalized name: Alglucosidase Alfa
DrugBank: Alglucosidase alfa (DB01272)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Alglucosidase alfa treatment for ≤13 years
Study: 38896602
Drug: Delgocitinib ointment
Normalized name: Delgocitinib
DrugBank: Delgocitinib (DB16133)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Delgocitinib ointment
Study: 38896602
Drug: Topical JAK
Normalized name: Janus-associated kinase (JAK) inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical JAK inhibition
Study: 38896602
Drug: Afatinib (EGFR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Afatinib (EGFR inhibitor)
Study: 38897097
Drug: Oral nomegestrol
Normalized name: nomegestrol
DrugBank: Nomegestrol acetate (DB13981)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Oral nomegestrol acetate/estradiol 1.5 mg/2.5 mg/day for 14 days (random start)
Study: 38897097
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no pharmaceutical treatment)
Study: 38897103
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (routine treatment and care)
Study: 38897155
Drug: Various treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Various treatments (248 treatments administered)
Study: 38897155
Drug: Short delay
Normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short delay from onset of relapse to treatment initiation
Study: 38897584
Drug: Mild hyperthermia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mild hyperthermia with MR-guided high intensity focused ultrasound (MR-HIFU) combined with concurrent chemoradiation (30.6 Gy in 1.8 Gy fractions with capecitabine)
Study: 38898018
Drug: Camrelizumab 200
Normalized name: Ocrelizumab
DrugBank: Ocrelizumab (DB11988)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Camrelizumab 200 mg on day 1 plus modified TPF (docetaxel 75 mg/m2) for three cycles
Study: 38898120
Drug: Entrectinib 600
Normalized name: ENTRECTINIB
DrugBank: Entrectinib (DB11986)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Entrectinib 600 mg daily
Study: 38898537
Drug: Enhanced treatment-as-usual
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced treatment-as-usual condition (TAU +)
Study: 38898573
Drug: Cardiac shockwave
Normalized name: Leonurus cardiaca extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cardiac shockwave therapy (SWT)
Study: 38899599
Drug: Steps 1-2
Normalized name: STEP 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steps 1-2 (non-surgical) of periodontal therapy (test group; n=37)
Study: 38899599
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (control group; n=37)
Study: 38899693
Drug: ViPOR (venetoclax,
Approvals — FDA: no, EMA: no, PMDA: no
Description: ViPOR (venetoclax, ibrutinib, prednisone, obinutuzumab, and lenalidomide) administered every 21 days for six cycles
Study: 38899695
Drug: CM313 (anti-CD38
Approvals — FDA: no, EMA: no, PMDA: no
Description: CM313 (anti-CD38 monoclonal antibody) administered intravenously at a dose of 16 mg/kg every week for 8 weeks
Study: 38899695
Drug: CM313 (anti-CD38
Approvals — FDA: no, EMA: no, PMDA: no
Description: CM313 (anti-CD38 monoclonal antibody)
Study: 38899776
Drug: Gamified delivery
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gamified delivery group (on-demand exercise videos and weekly exercise duration leaderboards)
Study: 38900037
Drug: Ibrutinib in
Normalized name: Product containing ibrutinib in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibrutinib in combination with R-GemOx (rituximab, gemcitabine, and oxaliplatin)
Study: 38900037
Drug: Ibrutinib in
Normalized name: Product containing ibrutinib in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibrutinib in combination with R-GemOx
Study: 38900435
Drug: SOR-TACE (sorafenib
Approvals — FDA: no, EMA: no, PMDA: no
Description: SOR-TACE (sorafenib 400 mg twice daily plus on-demand TACE)
Study: 38900984
Drug: SHR-A1811 (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHR-A1811 (1.0 to 8.0 mg/kg, IV, once every 3 weeks)
Study: 38900987
Drug: Fianlimab 1,600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fianlimab 1,600 mg and cemiplimab 350 mg intravenously once every 3 weeks for up to 51 weeks (with optional additional 51 weeks if clinically indicated)
Study: 38901008
Drug: Deutetrabenazine, mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deutetrabenazine, mean dose at week 145: 40.4 mg/d for psychotic disorders, 38.5 mg/d for mood and other disorders, 39.9 mg/d for those receiving DRAs, 38.5 mg/d for those not receiving DRAs.
Study: 38901293
Drug: Subcutaneous drain
Normalized name: pork brain preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous drain insertion
Study: 38901293
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no subcutaneous drain)
Study: 38901559
Drug: Insulin regulation
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin regulation in men with NASH
Study: 38901559
Drug: Insulin regulation
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin regulation in men with simple steatosis
Study: 38901946
Drug: Daytime infusions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daytime infusions of HPN
Study: 38901946
Drug: Overnight infusions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overnight infusions of HPN
Study: 38902005
Drug: LEV 20
Normalized name: guaifenesin / hydrocodone bitartrate / phenylephrine hydrochloride Oral Solution [Uni-Lev 5.0]
Approvals — FDA: no, EMA: no, PMDA: no
Description: LEV 20 or 40 mg/kg bolus followed by 5 or 10 mg/kg maintenance dose daily (NEOLEV1)
Study: 38902005
Drug: 40 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg/kg intravenous LEV load, followed by 10 mg/kg doses 8 hourly (NEOLEV2)
Study: 38902005
Drug: Further 20
Normalized name: HOMOSALATE 10 g in 100 mL / OCTOCRYLENE 7 g in 100 mL / OCTISALATE 5 g in 100 mL / AVOBENZONE 3 g in 100 mL TOPICAL LOTION [CO-BB-54431 Featuring You Hydrating Skin Enhancing Tint SPF30-270 FURTHER]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Further 20 mg/kg intravenous load if seizures persisted (NEOLEV2)
Study: 38902546
Drug: UB-312 (300/100/100
Approvals — FDA: no, EMA: no, PMDA: no
Description: UB-312 (300/100/100 μg)
Study: 38902571
Drug: ALZ-801 265
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALZ-801 265 mg tablet taken twice daily (after 2 weeks once daily)
Study: 38902572
Drug: ALZ-801 265
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALZ-801 265 mg two times daily (BID)
Study: 38902616
Drug: Tablet-based educational
Normalized name: DIABETES PATIENT EDUCATION PACK
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet-based educational control
Study: 38902691
Drug: Edaravone dexborneol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edaravone dexborneol (37.5 mg/12 hours, IV)
Study: 38902691
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no edaravone dexborneol treatment)
Study: 38902747
Drug: Aspirin and
Normalized name: Aspirin and Caffeine Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin and clopidogrel administration
Study: 38902846
Drug: InterCARE care
Approvals — FDA: no, EMA: no, PMDA: no
Description: InterCARE care model integrating HIV and hypertension care through provider training, adapted electronic health record, and treatment partners (peer support)
Study: 38902860
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of mRNA-1273 (100 μg)
Study: 38902860
Drug: Double dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double dose of mRNA-1273 (2×100 μg)
Study: 38902860
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of Ad26.COV2.S (adenovirus type 26 encoding the SARS-CoV-2 spike glycoprotein)
Study: 38902860
Drug: Discontinuation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinuation of mycophenolate mofetil/mycophenolic acid after vaccination
Study: 38902928
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg yohimbine and 10 mg hydrocortisone
Study: 38902952
Drug: Chemotherapy received
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy received locally
Study: 38902952
Drug: No chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: No chemotherapy received locally
Study: 38902994
Drug: nab-paclitaxel (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: nab-paclitaxel (150 mg/m2 in D1), oxaliplatin (85 mg/m2 in D1), S-1/leucovorin (35 mg/m2 and 30 mg bid from D1 to D7)
Study: 38903173
Drug: Concurrent taVNS
Normalized name: chlorpheniramine tannate Oral Tablet [Ed Chlor Tan]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent taVNS
Study: 38903173
Drug: Sequential taVNS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential taVNS
Study: 38903416
Drug: VR treatment
Normalized name: Prostin VR
DrugBank: Alprostadil (DB00770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: VR treatment (3D with binaural beats)
Study: 38903523
Drug: LVRNA012 mRNA
Normalized name: SARS-CoV-2 (COVID-19) vaccine, mRNA-1273 Injectable Suspension [Spikevax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: LVRNA012 mRNA vaccine (100ug)
Study: 38904126
Drug: Smoking cessation
Normalized name: Zyban 150 MG Smoking Cessation 12 HR Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Smoking cessation behavioural support sessions based on the 5As algorithm and a 6-week supply of nicotine replacement therapy
Study: 38904165
Drug: E4/DRSP (estetrol
Approvals — FDA: no, EMA: no, PMDA: no
Description: E4/DRSP (estetrol 15 mg)
Study: 38904646
Drug: NT-proBNP <125
Approvals — FDA: no, EMA: no, PMDA: no
Description: NT-proBNP <125 pg/mL
Study: 38904646
Drug: NT-proBNP ≥125
Approvals — FDA: no, EMA: no, PMDA: no
Description: NT-proBNP ≥125 pg/mL
Study: 38904657
Drug: Subjective reports
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjective reports of activities of daily living and other types of physical activity
Study: 38904892
Drug: Sacituzumab govitecan
Normalized name: sacituzumab govitecan
DrugBank: Sacituzumab govitecan (DB12893)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Sacituzumab govitecan (SG) with concomitant G-CSF
Study: 38904899
Drug: Amberen (dietary
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amberen (dietary supplement)
Study: 38904918
Drug: EVE +
Normalized name: Summer's Eve Medicated
Approvals — FDA: no, EMA: no, PMDA: no
Description: EVE + EXE (10 mg/day + 25 mg/day)
Study: 38904918
Drug: PBO +
Normalized name: INV-CIRB#20-18 (PREVENTABLE) ATORVASTATIN 40MG/PBO
Approvals — FDA: no, EMA: no, PMDA: no
Description: PBO + EXE (placebo + 25 mg/day)
Study: 38905148
Drug: PIEB settings
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PIEB settings (PIEBnb = 29.4 minutes, PIEBi = 59.8 minutes, PIEBv = 6.2 mL)
Study: 38905148
Drug: PCEA (volume
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCEA (volume 6 mL every 10 minutes)
Study: 38905212
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy for ADHD-I (CADDI)
Study: 38905476
Drug: Couple-based care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Couple-based care and treatment intervention
Study: 38905569
Drug: Fenofibrate (145-mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenofibrate (145-mg tablets daily or alternate days for those with impaired renal function)
Study: 38905580
Drug: Topical capsaicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical capsaicin (2 g of capsaicin ointment 0.075%) applied four times a day for 5 days
Study: 38905580
Drug: Placebo (matching
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (matching ointment)
Study: 38905608
Drug: Usual oral
Normalized name: HYDROGEN PEROXIDE 5 mg in 100 mL TOPICAL LIQUID [USUALKLENZ DISINFECTANTSPRAY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual oral care products and routine (control group; n = 12)
Study: 38905928
Drug: Reversal/replacement agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reversal/replacement agent administration during hospitalization (specific agents not detailed).
Study: 38906178
Drug: Cow milk
Normalized name: cow milk
DrugBank: Cow milk (DB10543)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cow milk antibody concentrations in cord blood
Study: 38906178
Drug: Cow milk
Normalized name: cow milk
DrugBank: Cow milk (DB10543)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cow milk antibody concentrations longitudinally from birth to 3 years
Study: 38906210
Drug: Relugolix combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Relugolix combination therapy (relugolix CT; 40 mg relugolix, 1 mg estradiol, and 0.5 mg norethisterone acetate)